KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Operations (2016 - 2025)

CRISPR Therapeutics AG's Cash from Operations history spans 11 years, with the latest figure at 92553000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 84.99% year-over-year to 92553000.0; the TTM value through Dec 2025 reached 345014000.0, down 141.65%, while the annual FY2025 figure was 345014000.0, 141.65% down from the prior year.
  • Cash from Operations for Q4 2025 was 92553000.0 at CRISPR Therapeutics AG, down from 84634000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 807002000.0 in Q2 2021 and bottomed at 141956000.0 in Q2 2022.
  • The 5-year median for Cash from Operations is 94067500.0 (2024), against an average of 35246600.0.
  • The largest annual shift saw Cash from Operations surged 2856.25% in 2021 before it plummeted 168.25% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 86038000.0 in 2021, then tumbled by 31.72% to 113328000.0 in 2022, then rose by 15.23% to 96073000.0 in 2023, then surged by 47.92% to 50031000.0 in 2024, then tumbled by 84.99% to 92553000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Cash from Operations are 92553000.0 (Q4 2025), 84634000.0 (Q3 2025), and 113880000.0 (Q2 2025).